SCHEMBL21756489

SCHEMBL21756489

CCN1CCN(c2cc(C)c(Nc3ncc(CCc4c(Cl)c(OC)cc(OC)c4Cl)cn3)c(N)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 11/20 0.47
▸ FGFR1 P11362 11/20 0.47
▸ FGFR2 P21802 6/20 0.44
▸ KDR P35968 4/20 0.44
▸ FGFR3 P22607 9/20 0.44
▸ PDGFRA P16234 3/20 0.38
▸ JAK2 O60674 2/20 0.38
▸ ABL1 P00519 2/20 0.38
▸ INSR P06213 2/20 0.38
▸ LCK P06239 2/20 0.38
▸ FYN P06241 2/20 0.38
▸ YES1 P07947 2/20 0.38
▸ LYN P07948 2/20 0.38
▸ RET P07949 2/20 0.38
▸ MET P08581 2/20 0.38
▸ ROS1 P08922 2/20 0.38
▸ KIT P10721 2/20 0.38
▸ SRC P12931 2/20 0.38
▸ BRAF P15056 2/20 0.38
▸ FLT1 P17948 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21386624 0.85 FGFR1 (0.48) FGFR4FGFR1FGFR2KDRFGFR3
SCHEMBL18134162 0.79 FGFR4 (0.71) FGFR4FGFR1FGFR2FGFR3
SCHEMBL18134032 0.77 FGFR1 (0.52) FGFR4FGFR1FGFR2FGFR3PDGFRA
SCHEMBL18134014 0.77 FGFR4 (0.51) FGFR4FGFR1FGFR2FGFR3
SCHEMBL18134167 0.76 FGFR4 (0.67) FGFR4FGFR1FGFR2FGFR3
SCHEMBL21386585 0.73 FGFR4 (0.52) FGFR4FGFR1FGFR2KDRFGFR3
SCHEMBL21756598 0.73 FGFR1 (0.48) FGFR4FGFR1FGFR2KDRFGFR3
SCHEMBL30262070 0.71 FGFR4 (0.46) FGFR4FGFR1FGFR2KDRFGFR3
SCHEMBL21756488 0.71 FGFR4 (0.68) FGFR4FGFR1FGFR2FGFR3
SCHEMBL21386669 0.71 FGFR1 (0.51) FGFR4FGFR1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2021-05-18 — — US disclosed
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2020-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof FGFR4, FGFR1, FGFR2 FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF FGFR4, FGFR1, FGFR2 FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback